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Background: Individual susceptibility to endogenous and/or exogenous DNA damage depends on DNA repair
efficiency and can be evaluated using the comet assay with bleomycin as genotoxic agent. The aim of the study
was to evaluate baseline and bleomycin-induced DNA damage and DNA repair capacity in peripheral blood
lymphocytes (PBLs) of endometrial cancer (EC) patients considering a family history of cancer.
Methods: DNA damage was analyzed in PBLs of 45 EC patients compared to a control group of 10 healthy
women, using the comet assay. The level of DNA damage was determined by the% tail DNA.
Results: The level of baseline DNA damage in PBLs of EC patients was significantly higher (% DNA in tail 9.31 ± 15.32)
than in healthy women (% DNA in tail 3.41 ± 4.71) (P <0.01). PBLs of EC patients repaired less bleomycin-induced DNA
damage (removed% DNA in tail 63.94 ± 20.92) than PBLs of healthy individuals (removed% DNA in tail 80.24 ± 3.03)
(P <0.001). Efficiency of DNA repair in PBLs of EC patients depended on the family history of cancer. The amount of
restored damaged DNA was significantly lower (removed% DNA in tail 36.24 ± 14.05%) in EC patients with a family
history of cancer compared to patients with sporadic EC (removed% DNA in tail 64.91 ± 19.36%) (P <0.004).
Conclusions: Lymphocytes of EC patients are characterized by an increased basal level of DNA damage as well as
deficiency in DNA repair. DNA repair is less efficient in PBLs of EC patients with a family history of cancer compared to
patients with sporadic cancer.
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The cell genome is constantly exposed to endogenous
and/or exogenous genotoxic agents causing structural
DNA changes which have potentially tremendous cellular
consequences. The ability of a cell to decrease or eliminate
entirely DNA damage depends on a variety of factors
including the nature of the DNA damage and efficiency of
DNA repair. A deficiency in DNA repair capacity leads to
greater DNA damage mediated by genotoxic agents and
may result in accumulated DNA damage. Both these fac-
tors exponentially contribute to increasing the risk for
cancer through genomic instability [1-3].* Correspondence: olha.brie@gmail.com
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article, unless otherwise stated.Human cancers have been shown to demonstrate
greater genomic instability compared with the normal
tissue in the same host. However, several studies report
genomic instability not only in cancer but also in som-
atic non-cancer cells of cancer patients, particularly in
peripheral blood lymphocytes (PBLs) [4-11]. These studies
hypothesize that the level of genome damage in PBLs
suggests an individual susceptibility to cancer [12-14].
To date, little is known about spontaneous genome
damage in PBLs of cancer patients with a family history
of cancer. Smith et al. did not find any correlation be-
tween DNA damage in PBLs of breast cancer patients
and a family history of cancer [12]. In contrast, Roy
et al. [13] have demonstrated that PBLs of breast cancer
patients and their healthy blood relatives with a family
history of cancer were highly sensitive to genotoxictral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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an increased level of chromosomal aberrations was
found in PBLs of colorectal cancer patients with a family
history of cancer [14].
It is well known that endometrial cancer (EC) may
arise within hereditary cancer syndromes (Lynch syn-
drome, Li-Fraumeni syndrome, etc.). In addition, pa-
tients with EC may have a family history of malignant
tumors of organs of the female reproductive system,
gastrointestinal tract and some others associated to
Lynch syndrome [15-17]. One study has reported the
presence of an increased frequency of chromosomal
aberrations and breaks at fragile sites of chromosomes
in PBLs from EC patients with a family history of cancer
compared to PBLs from EC patients without such a fam-
ily history [18]. The observed chromosomal instability in
PBLs may be caused either by inherited susceptibility to
genotoxic exposure or by low ability to repair DNA
lesions. Therefore, a study to evaluate the sensitivity of
PBLs to genotoxic mutagens and the DNA repair cap-
acity in EC patients with a family history of cancer is im-
portant. Such approach could contribute to an efficient
selection of family members at high risk for cancer and
help design cancer prevention strategies for individuals
at risk.
The aim of the study was to analyze the level of DNA
damage and DNA repair efficiency in peripheral blood
lymphocytes of EC patients, taking into account whether
or not they had a family history of cancer.
Methods
Forty five patients with endometrial cancer (EC) stage I
and II and ten healthy women were included in the study
after having obtained signed informed consent. The num-
ber of participants had sufficient statistical power to ob-
tain statistically significant results. EC patients underwent
surgical treatment at the gynecological oncology depart-
ment of the National Cancer Institute, Kyiv, Ukraine. All
studied tumors were classified as endometrioid adenocar-
cinomas. The mean age of the EC patients was 60 years,
while that of healthy individuals was 55.7 years. The study
was approved by the Committee for Ethical Issues of the
R.E. Kavetsky Institute of experimental pathology, on-
cology and radiobiology, National Academy of Sciences of
Ukraine.
A standardized questionnaire was used to collect infor-
mation on family history of cancer, age, work environment,
medications, smoking status, alcohol consumption and
nutritional factors. Only EC patients with approximately
the same lifestyle were included in this study. We selected
12 of the 40 (30%) of the EC patients with a strong family
history of cancers of female reproductive organs (endo-
metrium and ovary), gastrointestinal tract and some other
cancers associated to Lynch syndrome [15-17].Venous blood samples were obtained by venipuncture
and collected into EDTA tubes before patients had re-
ceived any chemotherapy or radiation therapy. Lympho-
cytes from whole blood were isolated by centrifugation
through Ficoll-Hypaque.
Analysis of baseline and bleomycin-induced DNA
damage was performed on freshly isolated PBLs using an
alkaline comet assay [19,20]. Briefly, microscope slides
were first covered with a 1% normal melting point agar-
ose. Then, 1 – 2 × 105 of cells were embedded into
75 μL of 1% low-melting point agarose at 37°C and the
gel was cast over the first agarose layer. To study geno-
toxic DNA damage, lymphocytes were treated with bleo-
mycin at concentration 20 μg/ml in phosphate buffered
saline (PBS), рН 7.4, for 30 min, as recommended by
Schmezer et al. [20]. DNA repair capacity was evaluated
as the extent of removal of damage in lymphocytes after
immersion slides into PBS without bleomycin and incu-
bation for 15 min, 37°C. As a positive control, lympho-
cytes treated with 100 μM Н2О2 for 5 min were used.
Then slides were immersed into a lysis solution (2.5 M
NaCl, 100 mM EDTA, 10 mM Tris, 10% DMSO, 1%
Triton X-100, pH10) and kept for an hour at 4°C. After
cell lysis, slides were placed in a horizontal gel electro-
phoresis unit filled with alkaline electrophoresis buffer
(300 mM NaOH, 1 mM EDTA, pH13). After 20 min of
alkali treatment, electrophoresis was performed for
20 min at 0.8 V/cm. Slides were then neutralized 2×10
min using neutralization buffer (0.4 M Tris, pH 7.5) and
stained with SYBR Green I. Comets were analyzed using
the computer-based image analysis system CometScore
(TriTek Corp., Sumerduck, VA, USA). The level of DNA
damage was expressed as% DNA in tail.
Data were analyzed using Statistica 8.0 (StatSoft, Inc.)
software. To compare differences between groups, the
Mann-Whitney nonparametric test was used with a sig-
nificance level of P <0.05.
Results
We observed a significantly (P <0.01) higher baseline
DNA damage in EC patients (% DNA in tail 9.31 ±
15.32) as compared with healthy individuals (% DNA in
tail 3.41 ± 4.71) (Table 1, Figure 1). The net bleomycin-
induced DNA damage was assessed by subtracting the
basal% DNA in tail from the% DNA in tail obtained after
incubating the PBLs with bleomycin. It was observed
that it didn’t differ significantly in EC patients (% DNA
in tail 89.35 ± 3.99) compared to healthy individuals
(% DNA in tail 84.20 ± 5.38). However, we found dif-
ferences after we removed bleomycin and studied DNA
damage repair. The level of DNA damage in PBLs
decreased within the first 15 min after removal of bleo-
mycin, both in healthy individuals and in EC patients
(Table 1, Figure 1). However, it was observed that the
Table 1 DNA damage in peripheral blood lymphocytes of EC patients
Groups of examined
patients (n =55)
% tail DNA mean ± SD
Baseline DNA damage Net bleomycin-induced DNA damage Removed DNA damage
Healthy individuals (n =10) 3.41 ± 4.71 84.20 ± 5.38 80.24 ± 3.03
EC patients (n =45) 9.31 ± 15.32* 89.35 ± 3.99 63.94 ± 20.92*
*Difference is significant in respect to the control group (р < 0.05).
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was significantly (P <0.001) lower (removed% DNA in
tail 63.94 ± 20.92) than in PBLs of control individuals
(removed% DNA in tail 80.24 ± 3.03). Most importantly,
we noted 80 - 100% recovery of bleomycin-induced
DNA damage in 70% of healthy individuals and in only
12% of EC patients (Figure 2).
To determine the significance of hereditary factor for
genetic instability in PBLs, we studied the level of base-
line DNA damage, bleomycin sensitivity and DNA repair
capacity in EC patients in relation to a family history ofFigure 1 Examples of DNA comets obtained by comet assay in periph
patients (B, D, F). A, B. Baseline DNA damages; C, D. DNA damage after bcancer. We did not observe any significant increase in
background DNA damage in PBLs of EC patients with a
family history of cancer (% DNA in tail 10.35 ± 16.35)
compared to those with no family history of cancer
(% DNA in tail 9.51 ± 15.71) (Table 2). The net bleomycin-
induced DNA damage also did not differ significantly
between the two groups (% tail DNA 91.09 ± 2.52 and
88.56 ± 4.25 respectively). However, significant difference
(P <0.004) in repair efficiency was found among these
patients. By further incubating cells in PBS without bleo-
mycin, PBLs of EC patients with a family history of cancereral blood lymphocytes of healthy individuals (A,C,E) and EC
leomycin exposure; E, F. DNA damage remained after repair.
Figure 2 Bleomycin-induced DNA damage removed in PBLs of healthy individuals and EC patients.
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(removed% tail DNA 36,24 ± 14,05) compared to patients
with no family history of cancer (removed% tail DNA
64,91 ± 19,36) (Table 2).
Discussion
The results of our study indicate that lymphocytes of EC
patients are characterized by pronounced genome in-
stability resulting in increased basal level of DNA dam-
age and deficiency in DNA repair. However one of the
limitations of this study was the small sample size we
did observed significantly higher baseline DNA damage
in EC patients than in healthy individuals which is in
agreement with other studies using the comet assay as
the study endpoint. Higher baseline DNA damage in
lymphocytes was observed in breast cancer patients in
comparison with healthy volunteers [11,12]. Kurzawa-
Zegota et al. showed that lymphocytes from colon
cancer patients had greater baseline DNA damage than
those from healthy individuals and this higher level of
damage was also observed throughout in vitro treatment
with genotoxins [21]. Moreover, in the study of Najafzadeh
et al. it has been identified that peripheral lymphocytes
from patients with cancers (malignant melanoma and
colorectal cancer) or their precancerous states were more
sensitive to a generic mutagen than lymphocytes from
healthy individuals [22]. The study of Schmezer et al. didTable 2 DNA damage in peripheral blood lymphocytes of EC
Groups of examined patients (n =40)
Baseline DNA damage
Patients with a family history of cancer (n =12) 10.35 ± 16.35
Patients with no family history of cancer (n =28) 9.51 ± 15.71
*Difference is significant in respect to the group of patients with a family history ofnot detect any significant difference between the levels of
baseline DNA damage in lymphocytes of lung cancer
patients and healthy individuals but found an increased
sensitivity of lymphocytes to bleomycin and decreased
DNA repair capacity in cancer patients [20]. The deficient
DNA repair in lymphocytes of lung, head and neck cancer
patients also has been shown by other researchers
[4,5,8,9]. It should be mentioned that the concentration of
bleomycin (20 μg/ml) recommended by Schmezer et al.,
which we also used in our study, caused DNA damage at
saturation level of the assay. Therefore, we consider
that in further research it is more appropriate to use
lower concentration of bleomycin, thus increasing the
accuracy of measurements of bleomycin sensitivity and
DNA repair.
There is no consensus on the causes of genetic insta-
bility in lymphocytes of cancer patients. Probably, genome
instability in lymphocytes is the result of the influence of
reactive oxygen species, increased levels of which were de-
tected in blood of cancer patients [23,24]. In this way, oxi-
dative stress is observed in breast, lung and colon cancer
patients [25-27]. In addition, DNA damage in lymphocytes
may also be influenced by tumor-associated factors [12].
Furthermore, reduced repair may lead to an increase in
the steady state level of DNA damage.
One study reported that family history of cancer did
not have a significant effect on the level of DNA damagepatients related to a family history of cancer
% tail DNA mean ± SD
Net bleomycin-induced DNA damage Removed DNA damage
91.09 ± 2.52 36.24 ± 14.05
88.56 ± 4.25 64.91 ± 19.36*
cancer (р < 0.05).
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correlation between a family history of cancer and DNA
damage in lymphocytes of EC patients. However, we
indeed observed lower DNA repair capacity in lympho-
cytes of EC patients with a family history of cancer.
Perhaps altered DNA repair may be caused by inherited
genetic defects and differences in DNA repair capacity
reflect individual genetic background leading to different
level of genetic instability [5].
We suggest that the comet assay with the use of bleo-
mycin as genotoxic agent is an acceptable way for identi-
fying EC patients with a high level of genome instability.
In addition, this assay might be a necessary step for de-
termination of individuals at high risk for cancer among
EC patients’ relatives. Further research on genome in-
stability in lymphocytes of cancer patients is needed to
investigate its significance for cancer prevention and to
identify how well these surrogate cells reflect events at
the level of the target tumor tissue.
Conclusions
The results of our study confirm the importance of
measuring the individual capacity to repair DNA damage
in EC patients especially in those with a family history of
cancer. In the present study, the DNA repair efficiency
significantly differs from controls to EC patients and
from EC patients with a family history of cancer to those
with sporadic cancer. We assume that reduced DNA
repair efficiency in peripheral blood lymphocytes of EC
patients may reflect the cancer predisposition.
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